Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 500 50 versus STERANE.
ADVAIR DISKUS 500/50 vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP, leading to bronchodilation. Fluticasone propionate is a corticosteroid with anti-inflammatory activity, inhibiting inflammatory cell infiltration and mediator release.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
ADVAIR DISKUS 500/50: One inhalation (fluticasone propionate 500 mcg and salmeterol 50 mcg) twice daily (approximately 12 hours apart).
100 mg orally every 12 hours
None Documented
None Documented
Fluticasone propionate: terminal elimination half-life is approximately 7.8 hours. Salmeterol: terminal elimination half-life is approximately 5.5 hours. Clinically, the half-life supports twice-daily dosing for sustained bronchodilation and anti-inflammatory effects.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Fluticasone propionate: primarily hepatic (cytochrome P450 3A4) metabolism; renal excretion accounts for <5% as unchanged drug; fecal excretion accounts for the majority as metabolites. Salmeterol: primarily hepatic metabolism; renal excretion accounts for approximately 25% of the dose; fecal excretion accounts for approximately 60%.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid